MedTrace Logo

Iron Intravenous Therapy in Reducing the Burden of Severe Arrhythmias in Heart Failure With Reduced Ejection Fraction

NCT04974021 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 106

Last updated 2021-07-23

No results posted yet for this study

Summary

An open label,single-center, non-interventional prospective study with the aim on investigating the effect of intravenous ferric carboxymaltose in restoring iron status and reducing the risk of severe arrhythmic events in participants with iron deficiency and a reduced ejection fraction (HFrEF).

Conditions

  • Ferric Carboxymaltose
  • Heart Failure With Reduced Ejection Fraction
  • Arrhythmias, Cardiac

Interventions

DRUG

Ferric carboxymaltose

Intravenous ferric carboxymaltose for the treatment of iron deficiency in HFrEF as per 2016 European Society of Cardiology Heart Failure guidelines.

Sponsors & Collaborators

  • Aristotle University Of Thessaloniki

    lead OTHER

Principal Investigators

  • Vassilios P Vassilikos, PhD · Hippokration General Hospital of Thessaloniki, Third Department of Cardiology, AUThi

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-20
Primary Completion
2021-08-30
Completion
2021-09-30
FDA Drug
Yes

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04974021 on ClinicalTrials.gov